<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00203125</url>
  </required_header>
  <id_info>
    <org_study_id>TVP - 1012/133a</org_study_id>
    <nct_id>NCT00203125</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.</brief_title>
  <official_title>Sub-study to Evaluate the Effect of An Oral Dose of Tyramine in Subjects Completing 26 Weeks of Participation in PRESTO (TVP-1012/133)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg
      of Rasagiline or Placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2000</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>An increase in systolic blood pressure of &gt; 30mmHg from the mean baseline value (documented by at least 3 consecutive measurements). Or Bradycardia with a heart rate below 40 beats per minute</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Parkinson's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rasagiline mesylate</intervention_name>
    <description>0.5 or 1 mg oral, once-daily</description>
    <other_name>TVP-1012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tyramine</intervention_name>
    <description>50 mg once daily</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women with idiopathic Parkinson's disease (PD) who have met inclusion criteria for
        PRESTO, and have completed the 26-week PRESTO study. The subject should be available to
        participate in the sub-study immediately following the last PRESTO visit (same day).
        Subjects must continue PRESTO study drug until the morning of the Tyramine Sub-Study.

        Subjects must provide separate informed consent to participate in the Tyramine Sub-Study.

        Exclusion Criteria:

        Subjects must not have a history of intracranial aneurysm or stroke.

        Subjects should not have uncontrolled hypertension, defined as systolic pressure &gt; 160
        mmHg, or diastolic pressure &gt; 90 mmHg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Salzman, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Teva Neuroscience, Inc.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 8, 2011</last_update_submitted>
  <last_update_submitted_qc>April 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>J. Michael Nicholas, Sr. Director, US Regulatory Affairs</name_title>
    <organization>Teva Neuroscience</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasagiline</mesh_term>
    <mesh_term>Tyramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

